- Home
- NYC vs MDAI Comparison
NYC vs MDAI Comparison
Compare NYC & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- MDAI
- Stock Information
- Founded
- NYC 2013
- MDAI 2013
- Country
- NYC United States
- MDAI United States
- Employees
- NYC N/A
- MDAI N/A
- Industry
- NYC Real Estate
- MDAI Medical/Dental Instruments
- Sector
- NYC Finance
- MDAI Health Care
- Exchange
- NYC Nasdaq
- MDAI Nasdaq
- Market Cap
- NYC 27.6M
- MDAI 27.8M
- IPO Year
- NYC N/A
- MDAI N/A
- Fundamental
- Price
- NYC $11.33
- MDAI $1.25
- Analyst Decision
- NYC
- MDAI Strong Buy
- Analyst Count
- NYC 0
- MDAI 2
- Target Price
- NYC N/A
- MDAI $4.75
- AVG Volume (30 Days)
- NYC 9.2K
- MDAI 341.2K
- Earning Date
- NYC 05-09-2025
- MDAI 05-06-2025
- Dividend Yield
- NYC N/A
- MDAI N/A
- EPS Growth
- NYC N/A
- MDAI N/A
- EPS
- NYC N/A
- MDAI N/A
- Revenue
- NYC $61,570,000.00
- MDAI $29,581,000.00
- Revenue This Year
- NYC $8.40
- MDAI N/A
- Revenue Next Year
- NYC $1.62
- MDAI $102.58
- P/E Ratio
- NYC N/A
- MDAI N/A
- Revenue Growth
- NYC N/A
- MDAI 63.83
- 52 Week Low
- NYC $5.46
- MDAI $0.82
- 52 Week High
- NYC $13.59
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- NYC 51.31
- MDAI 44.43
- Support Level
- NYC $11.13
- MDAI $1.17
- Resistance Level
- NYC $11.70
- MDAI $1.28
- Average True Range (ATR)
- NYC 0.98
- MDAI 0.09
- MACD
- NYC -0.05
- MDAI 0.02
- Stochastic Oscillator
- NYC 45.72
- MDAI 44.95
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.